Spectrum’s Research team has begun a new clinical study investigating the lifestyle, environmental and genomic factors which influence health outcomes for South Asian and European populations in Britain.
Originally developed in 2002, the London Life Sciences Prospective Population Study (LOLIPOP) is a major study aiming to help researchers develop a better understanding of the factors underlying metabolic and cardiovascular disease, which disproportionately affects South Asian populations.
- Diabetic and cardiovascular disease is two to four times more likely to occur in South Asian populations than in Europeans, for reasons that are not fully understood.
- To try and understand why this occurs and improve long-term health outcomes, the trial will recruit 100,000 people of South Asian and European descent and monitor their health over time. The study will run in several UK sites, including London.
- Eligible participants will be identified and invited to take part in the trial via local GP practices, day centres, community centres and mosques in Wakefield.
LOLIPOP recruitment clinics will also run 2 or 3 days per week from Spectrum’s Head Office at Navigation Walk, Wakefield. People interested in participating, you can register interest and book appointments via the LOLIPOP website, telephone, or email.
The study is sponsored by Imperial College London and delivered by Spectrum in partnership with Yorkshire and Humber Clinical Research Network (YHCRN), South West Yorkshire Partnership Foundation Trust (SWYFPT) and Conexus.